← boardnext 2026-12-31
CMND
Clearmind Medicine Inc.distress 4/10 · elevated risk$1.670%today-100% from 52w high
Lead: Alcohol Use Disorder
Revenue
pre-revenue
Liquidity
$14M
Runway
2.9 yrs
Shares 1y
0%
Price & events
-93.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
-16.3%
1W
-43.9%
1M
-79.6%
3M
-93.9%
6M
-99.6%
1Y
-99.7%
2Y
—
5Y
-100.0%
All
Overview
- Market Cap
- $263.20K
- Volume
- 27.36K
- 52 Week Range
- $1.64 – $476
- Total Shares
- 158.08K
- Float Shares
- 1.48M
- Short %
- 13.69%
- % Held by Insiders
- 0.09%
- % Held by Institutions
- 128.63%
- RVOL
- 0.03x
- Beta
- -1.19
Pipeline stages · 1 programs
CMND-100
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-31 Estimated 50% readout ~2027-02-14 | Phase 1/2 | CMND-100 | Alcohol Use Disorder | — | recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Recent news
- 2026-07-20Clearmind Medicine Files Hong Kong Patent Application for PTSD-Targeting Compounds - Quiver Quantitative
- 2026-07-20Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market - Yahoo Finance
- 2026-07-20Clearmind Medicine Expends Global IP portfolio with Hong - GlobeNewswire
- 2026-07-20Clearmind submits addiction treatment proposal to U.S. HHS By Investing.com - Investing.com Nigeria
- 2026-07-20Clearmind Medicine Expends Global IP Portfolio With Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‐Billion‐Dollar PTSD Therapeutics Market - Moomoo
- 2026-07-17Clearmind Medicine comments on federal psychedelic guidance By Investing.com - Investing.com Australia
- 2026-07-17Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction - The Manila Times
- 2026-07-17Clearmind Medicine comments on federal psychedelic guidance - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.